Dual diagnosis patients in clinical trials of antipsychotics

Journal of Dual Diagnosis

Volumn 3, Issue 2, 2007, Pages 73-83

  Adams, David H ^a   Liu Seifert, Hong ^a   Kinon, Bruce J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotics; Dual diagnosis; Schizophrenia; Substance abuse

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SUBSTANCE ABUSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34250709148     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1300/J374v03n02_09     Document Type: Conference Paper

References (15)

1. Dixon L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr Res. 1999;35:S93-100.
2. Cantor-Graae E, Nordström LG, McNeil TF. Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden. Schizophr Res. 2001;48:69-82.
3. Green AI. Schizophrenia and comorbid substance use disorder: Effects of antipsychotics. J Clin Psychiatry. 2005;66:S21-26.
4. Brunette MF, Mueser KT, Xie H, Drake RE. Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis. 1997;185:13-20.
5. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407-418.
6. Kinon BJ, Hill AL, Liu-Seifert H. Superiority of olanzapine versus quetiapine in improving overall functioning in schizophrenic patients with prominent negative symptoms. Biol Psychiatry. 2003;53:S25.
7. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM. Olanzapine versus ziprasidone: Results of the 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879-1887.
8. Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG.A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006;26:157-162.
9. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, Inc., 1992.
10. Noordsy DL, O'Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry. 1999;60(Suppl 19):47-51.
11. Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, Russo PA, Crown WH. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An instrument to assess outcomes of schizophrenia care. Schizophr Bull. 2003;29:247-256.
12. Gearon JS, Bellack AS. Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophrenia patients. Schizophr Res. 2000;43:65-70.
13. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3-38.
14. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophr Res. 2004;66:125-135.
15. Smelson D, Nyhuis AW, Faries DE, Tunis SL. Impact of substance use on attrition and medication switching in an effectiveness trial for individuals with schizophrenia: Implications for relapse prevention. Presented at the American Psychopathological Association national meeting; New York, NY; March 3-5, 2005.